ReviewBlood2012
Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.
Review in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 4 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6.Blood cancer journal · 2022Pooled it
- Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium.British journal of haematology · 2016Pooled it
- Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.Nature communications · 2015Pooled it
- European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.Haematologica · 2014Guideline
- MGUS in Black individuals in Soweto, South Africa screened by mass spectrometry: results of the PROMISE South Africa study.EClinicalMedicine · 2026Article
- Quantifying the contribution of modifiable risk factors for progression of MGUS to multiple myeloma in a Veteran population.International journal of cancer · 2026Article
- Article
- Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma.Blood neoplasia · 2025Article
- The Molecular Pathology of Blood Cancer: A Comprehensive Review of Chromosome and Genetic Abnormalities and Their Clinical Utility.British journal of biomedical science · 2025Review
- New horizons in our understanding of precursor multiple myeloma and early interception.Nature reviews. Cancer · 2024Review
- Influence of structural racism on cancer health disparities: Tailoring measures relevant to multiple myeloma.Cancer · 2024Article
- Anthropometric traits and risk of multiple myeloma: differences by race, sex and diagnostic clinical features.British journal of cancer · 2024Article
- A genetic risk score of alleles related to MGUS interacts with socioeconomic position in a population-based cohort.Scientific reports · 2022Article
- Review
- Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes.Human molecular genetics · 2021Article
- Germline variants at SOHLH2 influence multiple myeloma risk.Blood cancer journal · 2021Article
- Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance.Blood advances · 2020Article
- Role of Specific B-Cell Receptor Antigens in Lymphomagenesis.Frontiers in oncology · 2020Review
- Retracted Article: Long non-coding RNA PCAT1 facilitates cell growth in multiple myeloma through an MTDH-mediated AKT/β-catenin signaling pathway by sponging miR-363-3p.RSC advances · 2019Article
- Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies.Blood cancer journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma (MM), is one of the most common premalignant conditions in the general population. The cause of MGUS is largely unknown. Recent studies show that there is an increased prevalence of MGUS in blood relatives of persons with lymphoproliferative and plasma cell proliferative disorders, suggesting presence of shared underlying genetic influences. In the past few years, additional studies have examined risk factors and biologic characteristics that may contribute to the increased prevalence of MGUS among relatives of probands with MGUS, MM, and other blood malignancies. This article reviews the known epidemiology and risk factors for familial MGUS and myeloma, the risk of lymphoproliferative disorders and other malignancies among blood-relatives of patients with MGUS and MM, and discusses future directions for research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.